• Moore E, O'flaherty D, Heuvelmans H et al. (2000) A randomised comparison of generic sodium stibogluconate (sodium antimony gluconate, Albert David Ltd., Calcutta) and Pentostam (Glaxo Wellcome, London) for the Treatment of Visceral Leishmaniasis In Kenya. Bulletin of WHO, in press.
  • Seaman J, Pryce D, Sondorp E, Moody A, Bryceson ADM, Davidson RN (1993) Epidemic visceral leishmaniasis in Sudan: a randomised trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. Journal of Infectious Disease 168, 715 720.
  • Seaman J, Mercer A, Sondorp E (1996a) The epidemic of visceral leishmaniasis in Western Upper Nile, Southern Sudan: course and impact from 1984 to 1994. International Journal of Epidemiology 25, 862 871.
  • Seaman J, Mercer A, Sondorp E, Herwaldt B (1996b) Epidemic visceral leishmaniasis in Southern Sudan: treatment of severely debilitated patients under wartime conditions with limited resources. Annals of Internal Medicine 124, 664 672.
  • Sundar S, Sinha PR, Agrawal NK et al. (1998) A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. American Journal of Tropical Medicine and Hygiene 59, 139 143.
  • Undp/world Bank/WHO (1997) Progress 1995–96: 13th program report of the UNDP/World Bank/WHO special program for research and training in tropical diseases. World Health Organization, Geneva.
  • WHO (1996) Manual on Visceral Leishmaniasis Control. World Health Organization, Geneva.